Impaired endothelial cell proliferation has been proposed to be an early, critical defect contributing to the development of atherosclerosis. Recent studies show that high plasma tumor necrosis factor (TNF)-α levels and low serum ascorbic acid (AA) levels correlate with atherosclerosis severity. Additionally, AA has been reported to have potential beneficial effects in preventing atherosclerosis. Based on these studies, we investigated the role of AA (≤ 1mM) on TNF-α-mediated vascular endothelial cell growth inhibition in vitro. In accordance with previous reports, we found that TNF-α alone inhibited endothelial cell proliferation. Further studies revealed that AA alone enhanced endothelial cell proliferation and that AA blocked endothelial cell growth inhibition induced by TNF-α. By contrast, we observed no effect of AA on endothelial cell activation or nuclear entry of nuclear factor-κB in response to TNF-α. The protective effect of AA on endothelial cell proliferation was not simply the result of its antioxidant activity but did correlate with collagen IV expression by endothelial cells. AA pre-treatment of proliferating endothelial cells promoted retinoblastoma protein (Rb) phosphorylation and decreased p53 levels when compared to untreated cells. Furthermore, the addition of AA to TNF-α-treated proliferating endothelial cells blocked both the inhibition of retinoblastoma protein phosphorylation and enhanced p53 expression induced by TNF-α. Consistent with these results, we found that AA protects endothelial cells against TNF-α-induced apoptosis. These studies highlight the potential therapeutic role of AA in promoting endothelial cell proliferation during inflammatory conditions, such as atherosclerosis and cardiovascular disease.
Get full access to this article
View all access options for this article.
References
1.
Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood91:3527–3561, 1998.
2.
Montrucchio G, Lupia E, Battaglia E, Passerini G, Bussolino F, Emanuelli G, Camussi G. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med180:377–382, 1994.
3.
Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature329:630–632, 1987.
4.
Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA84:5277–5281, 1987.
5.
Sato N, Goto T, Haranaka K, Satomi N, Nariuchi H, Mano-Hirano Y, Sawasaki Y. Actions of tumor necrosis factor on cultured vascular endothelial cells: Morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst76:1113–1121, 1986.
6.
Yilmaz A, Bieler G, Spertini O, Lejeune FJ, Ruegg C. Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. Int J Cancer77:592–599, 1998.
7.
Schweigerer L, Malerstein B, Gospodarowicz D. Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem Biophys Res Commun143:997–1004, 1987.
8.
Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med4:408–414, 1998.
9.
Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem275:11216–11221, 2000.
10.
Lopez-Marure R, Bernal AE, Zentella A. Interference with c-myc expression and RB phosphorylation during TNF-mediated growth arrest in human endothelial cells. Biochem Biophys Res Commun236:819–824, 1997.
11.
Lopez-Marure R, Ventura JL, Sanchez L, Montano LF, Zentella A. Ceramide mimics tumour necrosis factor-alpha in the induction of cell cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/protein levels. Eur J Biochem267:4325–4333, 2000.
12.
Nakagami H, Cui TX, Iwai M, Shiuchi T, Takeda-Matsubara Y, Wu L, Horiuchi M. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler Thromb Vasc Biol22:238–242, 2002.
13.
Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol121:255–260, 2000.
14.
Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, Bond MG, de Faire U, Nilsson J, Eriksson P, Hamsten A. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J23:376–383, 2002.
15.
Lynch SM, Gaziano JM, Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. Subcell Biochem25:331–367, 1996.
16.
Nakata Y, Maeda N. Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to make ascorbic acid. Circulation105:1485–1490, 2002.
17.
Salonen JT, Nyyssonen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Lakka TA, Rissanen T, Leskinen L, Tuomainen TP, Valkonen VP, Ristonmaa U, Poulsen HE. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med248:377–386, 2000.
18.
Neuzil J, Thomas SR, Stocker R. Requirement for, promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radic Biol Med22:57–71, 1997.
19.
Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation103:1863–1868, 2001.
20.
Kunz J. Proliferation, migration and cell renewal within the arterial wall. Acta Histochem Suppl27:233–243, 1983.
21.
Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol33:1673–1690, 2001.
22.
Rossig LS, Dimmeler S, Zeiher AM. Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol96:11–22, 2001.
23.
Rossig LJ, Hoffmann J, Hugel B, Mallat Z, Haase A, Freyssinet JM, Tedgui A, Aicher A, Zeiher AM, Dimmeler S. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation104:2182–2187, 2001.
24.
Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA98:9842–9846, 2001.
25.
Relou IA, Damen CA, van der Schaft DW, Groenewegen G, Griffioen AW. Effect of culture conditions on endothelial cell growth and responsiveness. Tissue Cell30:525–530, 1998.
26.
Branch DR, Shah A, Guilbert LJ. A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors. J Immunol Methods143:251–261, 1991.
27.
Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem275:5096–5103, 2000.
28.
Wu D, Koga T, Martin KR, Meydani M. Effect of vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis147:297–307, 1999.
29.
Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest94:592–600, 1994.
30.
Bowie AG, O’Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol165:7180–7188, 2000.
31.
Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J15:2423–2432, 2001.
32.
Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol12:141–179, 1994.
33.
Bowie AG, Moynagh PN, O’Neill LA. Lipid peroxidation is involved in the activation of NF-kappaB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. Lack of involvement of H2O2 in NF-kappaB activation by either cytokine in both primary and transformed endothelial cells. J Biol Chem272:25941–25950, 1997.
34.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J13:9–22, 1999.
35.
Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res253:117–130, 1999.
36.
Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest98:490–496, 1996.
37.
Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, Klagsbrun M, Ferrara N, Bussolino F. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem273:22128–22135, 1998.
38.
Sage H, Pritzl P, Bornstein P. Endothelial cells secrete a novel collagen type in vitro independently of prolyl hydroxylation. Coll Relat Res2:465–479, 1982.
39.
Mahmoodian F, Peterkofsky B. Vitamin C deficiency in guinea pigs differentially affects the expression of type IV collagen, laminin, and elastin in blood vessels. J Nutr129:83–91, 1999.
40.
Form DM, Pratt BM, Madri JA. Endothelial cell proliferation during angiogenesis. In vitro modulation by basement membrane components. Lab Invest55:521–530, 1986.
41.
Funyu J, Mochida S, Inao M, Matsui A, Fujiwara K. VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells. Biochem Biophys Res Commun280:481–485, 2001.
42.
Albuquerque ML, Waters CM, Savla U, Schnaper HW, Flozak AS. Shear stress enhances human endothelial cell wound closure in vitro. Am J Physiol Heart Circ Physiol279:H293–H302, 2000.
43.
Genersch E, Hayess K, Neuenfeld Y, Haller H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: Involvement of Ras-dependent and -independent pathways. J Cell Sci113:4319–4330, 2000.
44.
Kawauchi J, Zhang C, Nobori K, Hashimoto Y. T Adachi M, Noda A, Sunamori M, Kitajima S. Transcriptional repressor ATF3 protects human umbilical vein endothelial cells from TNF-alpha–induced apoptosis through down-regulation of p53 transcription. J Biol Chem277:39025–39034, 2002.
45.
Jin HM, Liu QH, Cao X, Wu ZH, Zhang GP, Zhang M, Sha ZY. Dysfunction of microvascular endothelial cells induced by tumor necrosis factor (TNFalpha): cellular and molecular mechanism. Clin Hemorheol Microcirc23:109–112, 2000.
46.
Meerarani P, Ramadass P, Toborek M, Bauer HC, Bauer H, Hennig B. Zinc protects against apoptosis of endothelial cells induced by linoleic acid and tumor necrosis factor alpha. Am J Clin Nutr71:81–87, 2000.
47.
Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol88:10–15, 2001.
48.
Deshpande SS, Angkeow P, Huang J, Ozaki M, Irani K. Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J14:1705–1714, 2000.
49.
Wu F, Tyml K, Wilson JX. Ascorbate inhibits iNOS expression in endotoxin- and IFN gamma-stimulated rat skeletal muscle endothelial cells. FEBS Lett520:122–126, 2002.
50.
Hediger MA. New view at C. Nat Med8:445–446, 2002.
51.
Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA98:9842–9846, 2001.
52.
Sakagami H, Satoh K, Fukuchi K, Gomi K, Takeda M. Effect on an iron-chelator on ascorbate-induced cytotoxicity. Free Radic Biol Med23:260–270, 1997.
53.
Schmidt RJ, Chung LY, Andrews AM, Turner TD. Toxicity of L-ascorbic acid to L929 fibroblast cultures: relevance to biocompatibility testing of materials for use in wound management. J Biomed Mater Res27:521–527, 1993.
54.
Hanashima C, Namiki H. Reduced viability of vascular endothelial cells by high concentration of ascorbic acid in vitreous humor. Cell Biol Int23:287–298, 1999.
55.
Harris SR, Panaro NJ, Thorgeirsson UP. Oxidative stress contributes to the anti-proliferative effects of flavone acetic acid on endothelial cells. Anticancer Res20:2249–2254, 2000.
56.
Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol106:148–156, 2001.
57.
Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM, Losordo DW. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: Balance between growth and death signals. J Mol Cell Cardiol29:1321–1330, 1997.
58.
Maragoudakis ME, Sarmonika M, Panoutsacopoulou M. Inhibition of basement membrane biosynthesis prevents angiogenesis. J Pharmacol Exp Ther244:729–733, 1988.
59.
McAuslan BR, Reilly W, Hannan GN, Schindhelm K, Milthorpe B, Saur BA. Induction of endothelial cell migration by proline analogs and its relevance to angiogenesis. Exp Cell Res176:248–257, 1988.
60.
Thiele J, Rompcik V, Wagner S, Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: An immuno-morphometric study on trephine biopsies of the bone marrow. Br J Haematol80:227–234, 1992.
61.
Mercier P, Ekindjian OG. Collagen type IV: major component of basement membranes. Current knowledge. Ann Biol Clin (Paris)48:695–711, 1990.
62.
Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: Relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr54:1135S–1140S, 1991.
63.
Rixen H, Kirkpatrick CJ, Schmitz U, Ruchatz D, Mittermayer C. Interaction between endothelial cells and basement membrane components. In vitro studies on endothelial cell adhesion to collagen types I, III, IV and high molecular weight fragments of IV. Exp Cell Biol57:315–323, 1989.
64.
Meredith JE Jr, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell4:953–961, 1993.
65.
Shekhonin BV, Domogatsky SP, Idelson GL, Koteliansky VE, Rukosuev VS. Relative distribution of fibronectin and type I, III, IV, V collagens in normal and atherosclerotic intima of human arteries. Atherosclerosis67:9–16, 1987.
66.
Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis12:168–184, 1992.
67.
Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J296:803–809, 1993.
68.
Yao J, Bone RC, Sawhney RS. Differential effects of tumor necrosis factor-alpha on the expression of fibronectin and collagen genes in cultured bovine endothelial cells. Cell Mol Biol Res41:17–28, 1995.
69.
Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem378:151–160, 1997.
70.
Schwartz MA, Schaller MD, Ginsberg MH. Integrins: Emerging paradigms of signal transduction. Annu Rev Cell Dev Biol11:549–599, 1995.
71.
Buckley S, Driscoll B, Anderson KD, Warburton D. Cell cycle in alveolar epithelial type II cells: Integration of Matrigel and KGF. Am J Physiol273:L572–L580, 1997.
72.
Roy J, Tran PK, Religa P, Kazi M, Henderson B, Lundmark K, Hedin U. Fibronectin promotes cell cycle entry in smooth muscle cells in primary culture. Exp Cell Res273:169–177, 2002.
73.
Takahashi K, Suzuki K, Uehara Y, Ono T. Growth inhibition by anchorage-deficiency is associated with increased level but reduced phosphorylation of mutant p53. Japan J Cancer Res83:358–365, 1992.
74.
Wu RC, Schonthal AH. Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem272:29091–29098, 1997.
75.
Lassus P, Roux P, Zugasti O, Philips A, Fort P, Hibner U. Extinction of rac1 and Cdc42Hs signalling defines a novel p53-dependent apoptotic pathway. Oncogene19:2377–2385, 2000.
76.
Pohlman TH, Harlan JM. Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis. Cell Immunol119:41–52, 1989.
77.
Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem271:27201–27204, 1996.
78.
Slowik MR, Min W, Ardito T, Karsan A, Kashgarian M, Pober JS. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways. Lab Invest77:257–267, 1997.
79.
Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB. Induction of endothelial cell apoptosis by TNF alpha: modulation by inhibitors of protein synthesis. Exp Cell Res214:584–594, 1994.
80.
Emmanuel C, Foo E, Medbury HJ, Matthews J, Comis A, Zoellner H. Synergistic induction of apoptosis in human endothelial cells by tumour necrosis factor-alpha and transforming growth factor-beta. Cytokine18:237–241, 2002.
